Oncotarget

Corrections:

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET

PDF  |  How to cite

Oncotarget. 2018; 9:34641-34641. https://doi.org/10.18632/oncotarget.26214

Metrics: PDF 1718 views  |   ?  

Ido D. Weiss1, Lyn M. Huff2, Moses O. Evbuomwan3, Xin Xu1, Hong Duc Dang1, Daniel S. Velez1, Satya P. Singh1, Hongwei H. Zhang1, Paul J. Gardina4, Jae-Ho Lee5, Liza Lindenberg6, Timothy G. Myers4, Chang H. Paik5, David S. Schrump7, Stefania Pittaluga3, Peter L. Choyke6, Tito Fojo2 and Joshua M. Farber1

1 Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
2 Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
3 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
4 Genomic Technologies Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
5 Radiopharmaceutical Laboratory, Nuclear Medicine Division, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA
6 Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
7 Thoracic Epigenetics Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Published: October 02, 2018

This article has been corrected:

On page 73395, the following sentences have been updated to read, "Dosimetry for 64Cu- plerixafor calculated from this single patient gave an Effective Dose of 0.283 rem/mCi, and a total of 2.43 rem from the dose of 8.6 mCi. The organs that contributed the most to the Effective Dose were the liver and bone marrow (0.0606 and 0.0760 rem/mCi, respectively)".

Similar to results in mice, the liver had the highest uptake of the tracer, with unbound tracer excreted through the kidneys [31, 32]. Significant uptake was also seen in organs of the immune system, including spleen, vertebral bodies (bone marrow), and lymph nodes (Figure 4 and Supplementary Figure 6). Of additional interest, uptake of 64Cu-plerixafor was absent from a number of vertebral bodies in the thoracolumbar spine that were within the region of prior radiation therapy (Figure 4 and Supplementary Figure 6). Dosimetry for 64Cu-plerixafor calculated from this single patient gave an Effective Dose of 0.283 rem/mCi, and a total of 2.43 rem from the dose of 8.6 mCi. The organs that contributed the most to the Effective Dose were the liver and bone marrow (0.0606 and 0.0760 rem/mCi, respectively). PET/CT sections (Figure 4B) showed variable uptake in the multiple pulmonary nodules.

Original article: Oncotarget. 2017; 8:73387-73406. DOI: https://doi.org/10.18632/oncotarget.19945.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26214